Influence of type 2 sodium-glucose co-transporter inhibitors (dapagliflozin) on the indicators of total mortality in patients with type 2 diabetes (CARDIA-MOS study, Moscow)

Influence of type 2 sodium-glucose co-transporter inhibitors (dapagliflozin) on the indicators of total mortality in patients with type 2 diabetes (CARDIA-MOS study, Moscow)

BACKGROUND: The widespread use in clinical practice of drugs with cardio- and nephroprotective properties, in particular, sodium-glucose cotransporter type 2 inhibitors (SGLT2i), is based on the results of large-scale international randomized trials. Meanwhile, there are no data demonstrating the po...

Full description

Bibliographic Details
Main Authors:	M. B. Antsiferov, N. A. Demidov, M. A. Balberova, O. V. Lobanova, I. G. Mudrikova, D. G. Gusenbekova
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2022-12-01
Series:	Сахарный диабет
Subjects:	type 2 diabetes mellitus dapagliflozin sglt2i relative risk of death cvd chf ckd
Online Access:	https://www.dia-endojournals.ru/jour/article/view/12929

Similar Items

INFLUENCE OF TYPE 2 SODIUM-GLUCOSE CO-TRANSPORTER INHIBITORS (DAPAGLIFLOZIN) ON THE INDICATORS OF TOTAL MORTALITY IN PATIENTS WITH TYPE 2 DIABETES (CARDIA-MOS STUDY, MOSCOW)
by: Mikhail B. Antsiferov, et al.
Published: (2022-12-01)

Dapagliflozin effectiveness in improvement of clinical outcomes in diabetic patients (extention of CARDIA-MOS study, Moscow)
by: M. B. Antsiferov, et al.
Published: (2025-02-01)

Clinical Evaluation of Dapagliflozin in the Management of CKD: Focus on Patient Selection and Clinical Perspectives
by: Nashar K, et al.
Published: (2022-11-01)

Impact of dapagliflozin on life expectancy in type 2 diabetes mellitus patients in routine practice
by: M. B. Antsiferov, et al.
Published: (2023-08-01)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
by: Julio Rosenstock, et al.

Implications of CVD-REAL 2 study for Indian diabetic population
by: Rajeev Chawla, et al.
Published: (2019-01-01)

Benefit or Risk in Patient with Type 1 Diabetes Based on Appropriated Dosage of Dapagliflozin: A Case Report
by: Yan Tian, et al.
Published: (2023-04-01)

Dapagliflozin: A new hope for the therapeutic treatment of type 2 diabetes mellitus
by: Naazneen Maksud, et al.
Published: (2024-08-01)

Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease
by: Minara S. Shamkhalova, et al.
Published: (2022-11-01)

Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
by: Olga Yuryevna Sukhareva, et al.
Published: (2016-01-01)

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
by: Avgerinos I, et al.
Published: (2019-12-01)

Comparison of Extraglycemic effects of Dapagliflozin and Empagliflozin
by: Haroon Aziz, et al.
Published: (2023-06-01)

The effects of dapagliflozin on serum electrolytes concentration in adult male rats
by: Muhsin S. G. Al-Mozie'l, et al.
Published: (2018-12-01)

Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes
by: Shi Tai, et al.
Published: (2023-08-01)

Management of Diabetes Associated with Nephrotic Syndrome: Therapeutic Potential of Dapagliflozin for Protracted Volume Retention
by: Toshimi Imai, et al.
Published: (2015-11-01)

Safety assessment of dapagliflozin: Real-world adverse event analysis based on the FAERS database from 2012 to 2023
by: Zhengxi Zhou, et al.
Published: (2024-06-01)

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
by: Kuecker CM, et al.
Published: (2016-02-01)

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation
by: Rhona Johnston, et al.
Published: (2017-01-01)

Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism
by: Yvo J.M. op den Kamp, et al.
Published: (2022-12-01)

Cardiovascular outcomes of dapagliflozin in type 2 diabetes mellitus in real clinical practice: a meta-analysis of observational studies
by: Mikhail B. Antsiferov, et al.
Published: (2023-07-01)

Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus
by: Hyun A Cho, et al.
Published: (2017-06-01)

Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial
by: Riobaldo M. R. Cintra, et al.
Published: (2019-07-01)

Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis
by: Zepeng Shi, et al.
Published: (2022-04-01)

SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice
by: Dustin M. Lee, et al.
Published: (2018-04-01)

Dapagliflozin Does Not Protect against Adriamycin-Induced Kidney Injury in Mice
by: Jin Joo Cha, et al.
Published: (2024-01-01)

Sodium–glucose co-transporter-2 inhibitors - empagliflozin and dapagliflozin as future therapy for Alport Syndrome, literature review
by: Magdalena Kłusek, et al.
Published: (2024-07-01)

Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan
by: Jung-Fu Chen, et al.
Published: (2020-11-01)

Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis
by: Ahmed E. Ali, et al.
Published: (2023-08-01)

Sodium–glucose cotransporter‐2 inhibitors induced euglycemic diabetic ketoacidosis: Two case reports and a review of the literature
by: Zouheir Ibrahim Bitar, et al.
Published: (2022-02-01)

Dapagliflozin in peritoneal dialysis patients: a pilot study evaluating peritoneal membrane function
by: Zakaria Hamdan, et al.
Published: (2024-01-01)

Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01)

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial
by: Glenn M. Chertow, et al.
Published: (2023-05-01)

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial
by: Charlotte C. van Ruiten, et al.
Published: (2022-04-01)

Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study
by: Dimitrios Patoulias, et al.
Published: (2022-08-01)

Practice of Dapagliflozin Application in Patients with Type 2 Diabetes Mellitus
by: L.V. Shkala, et al.
Published: (2015-08-01)

Dapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through β-hydroxybutyrate production
by: Yan Tian, et al.
Published: (2025-12-01)

Role of Metformin Monotherapy Vs Metformin Plus Dapagliflozin in New Onset T2DM Among 40 Plus Obese Women in Glycaemic Control
by: Amarjeet Singh, et al.
Published: (2024-10-01)

A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
by: Chang Hee Jung, et al.
Published: (2014-08-01)

Divergent electrophysiologic action of dapagliflozin and empagliflozin on ventricular and atrial tachyarrhythmias in isolated rabbit hearts
by: Julian Wolfes, et al.
Published: (2024-02-01)

Determining the Role of SGLT2 Inhibition with Dapagliflozin in the Development of Diabetic Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2022-12-01)